-
1
-
-
20244372077
-
Therapeutic strategies for rheumatoid arthritis
-
O'DELL JR: Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004; 350: 2591-602.
-
(2004)
N Engl J Med
, vol.350
, pp. 2591-2602
-
-
O'DELL, J.R.1
-
2
-
-
35448956495
-
Rheumatoid arthritis: Diagnosis and management
-
MAJITHIA V, GERACI SA: Rheumatoid arthritis: diagnosis and management. Am J Med 2006; 120: 936-9.
-
(2006)
Am J Med
, vol.120
, pp. 936-939
-
-
MAJITHIA, V.1
GERACI, S.A.2
-
3
-
-
0035056003
-
Anti-TNF-α therapy of rheumatoid arthritis: What have we learned?
-
FELDMANN M, MAINI RN: Anti-TNF-α therapy of rheumatoid arthritis: What have we learned? Annu Rev Immunol 2001; 19:163-96.
-
(2001)
Annu Rev Immunol
, vol.19
, pp. 163-196
-
-
FELDMANN, M.1
MAINI, R.N.2
-
4
-
-
33947588655
-
Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab
-
POI D, PERIN A, MORASSI MP: Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab. Clin Exp Rheumatol 2007; 1: 85-7.
-
(2007)
Clin Exp Rheumatol
, vol.1
, pp. 85-87
-
-
POI, D.1
PERIN, A.2
MORASSI, M.P.3
-
5
-
-
14844345548
-
Anakinra: Review of recombinant human interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis
-
FURST D: Anakinra: review of recombinant human interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther 2004; 26: 1960-75.
-
(2004)
Clin Ther
, vol.26
, pp. 1960-1975
-
-
FURST, D.1
-
6
-
-
33746961890
-
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
-
COHEN SB, EMERY P, GREENWALD MW et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 2793-2806
-
-
COHEN, S.B.1
EMERY, P.2
GREENWALD, M.W.3
-
7
-
-
47949111861
-
Abatacept inhibits structural damage progression in rheumatoid arthritis: Results from the long-term extension of the AIM trial
-
GENANT HK PETERFY CG, WESTHOVENS R et al.: Abatacept inhibits structural damage progression in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008; 67: 1084-9.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 1084-1089
-
-
GENANT, H.K.1
PETERFY, C.G.2
WESTHOVENS, R.3
-
8
-
-
33846090262
-
Retention rates of tumor necrosis factor blockers in daily practice in 770 Rheumatic Patients
-
DUCLOS M, GOSSEC L, RUYESSEN-WITRAND A et al.: Retention rates of tumor necrosis factor blockers in daily practice in 770 Rheumatic Patients. J Rheumatol 2006; 33: 2433-9.
-
(2006)
J Rheumatol
, vol.33
, pp. 2433-2439
-
-
DUCLOS, M.1
GOSSEC, L.2
RUYESSEN-WITRAND, A.3
-
9
-
-
34347225530
-
Open label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: The opposite study
-
FURST D, GAYLIS N, BRAY V et al.: Open label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 2007; 66: 893-9.
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 893-899
-
-
FURST, D.1
GAYLIS, N.2
BRAY, V.3
-
10
-
-
34247611914
-
Therapy of patients with rheumatoid arthritis: Outcome of infliximab failures switched to etanercept
-
BUCH MH, BINGHAM SJ, BEJARANO V et al.: Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum 2007; 57: 448-53.
-
(2007)
Arthritis Rheum
, vol.57
, pp. 448-453
-
-
BUCH, M.H.1
BINGHAM, S.J.2
BEJARANO, V.3
-
11
-
-
33846875483
-
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects
-
IANNONE F, TROTTA F, MONTECCUCO C et al.: Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 2007; 66: 249-52.
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 249-252
-
-
IANNONE, F.1
TROTTA, F.2
MONTECCUCO, C.3
-
12
-
-
33846239331
-
Outcomes after switching from one anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study
-
HYRICH K, LUNT M, WATSON KD et al.: Outcomes after switching from one anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis Rheum 2007; 56: 13-20.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 13-20
-
-
HYRICH, K.1
LUNT, M.2
WATSON, K.D.3
-
13
-
-
70350605186
-
Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period Arthritis Res
-
GOMEZ-REINO JJ, CARMONA L et al.: Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period Arthritis Res Ther 2006; 8: R29 1-7.
-
(2006)
Ther
, vol.8
, Issue.R29
, pp. 1-7
-
-
GOMEZ-REINO, J.J.1
CARMONA, L.2
-
14
-
-
0345490890
-
Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: Data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense
-
VAN VOLLENHOVEN R, HARJU A, BRANNEMAR S et al.: Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003; 62: 1195-8.
-
(2003)
Ann Rheum Dis
, vol.62
, pp. 1195-1198
-
-
VAN VOLLENHOVEN, R.1
HARJU, A.2
BRANNEMAR, S.3
-
15
-
-
38149024108
-
Rituximab therapy in rheumatoid arthritis in daily practice
-
ASSOUS N, GOSSEC L, DIEUDE P et al.: Rituximab therapy in rheumatoid arthritis in daily practice. J Rheumatol 2008; 35: 31-4.
-
(2008)
J Rheumatol
, vol.35
, pp. 31-34
-
-
ASSOUS, N.1
GOSSEC, L.2
DIEUDE, P.3
-
16
-
-
41349091216
-
Cardiovascular outcomes in male veterans with rheumatoid arthritis
-
BANERJEE S, COMPTON AP, HOOKER RS et al.: Cardiovascular outcomes in male veterans with rheumatoid arthritis Am J Cardiol 2008; 101: 1201-5.
-
(2008)
Am J Cardiol
, vol.101
, pp. 1201-1205
-
-
BANERJEE, S.1
COMPTON, A.P.2
HOOKER, R.S.3
-
17
-
-
0023945481
-
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
-
ARNETT, FC, EDWORTHY SM et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
-
(1988)
Arthritis Rheum
, vol.31
, pp. 315-324
-
-
ARNETT, F.C.1
EDWORTHY, S.M.2
-
18
-
-
0031715621
-
Validation of rheumatoid arthritis improvement criteria that include simplified joint counts
-
VAN GESTEL, AM, HAAGSMA CJ et al.: Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 1845-50.
-
(1998)
Arthritis Rheum
, vol.41
, pp. 1845-1850
-
-
VAN GESTEL, A.M.1
HAAGSMA, C.J.2
-
19
-
-
43049162899
-
Treatment response to a second or third TNF-inhibitor in RA: Results from the South Swedish Arthritis Treatment Group Register
-
KARLSON JA, KRISTEN LE, KAPETANOVIC MC et al.: Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 2008; 47: 507-13.
-
(2008)
Rheumatology
, vol.47
, pp. 507-513
-
-
KARLSON, J.A.1
KRISTEN, L.E.2
KAPETANOVIC, M.C.3
-
20
-
-
29944442627
-
The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis
-
COHEN G, COURVOISIER N, COHEN JD et al.: The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: 795-800.
-
(2005)
Clin Exp Rheumatol
, vol.23
, pp. 795-800
-
-
COHEN, G.1
COURVOISIER, N.2
COHEN, J.D.3
-
21
-
-
32144446399
-
-
BATHON JM, FLEISCHMANN RM, VAN DER HEIJDE DM et al.: Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006; 33: 234-43.
-
BATHON JM, FLEISCHMANN RM, VAN DER HEIJDE DM et al.: Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006; 33: 234-43.
-
-
-
-
22
-
-
33144490233
-
Long term safety of etanercept in elderly subjects with rheumatic diseases
-
FLEISCHMANN R, BAUMGARTNER SW, WEISMAN MH et al.: Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006; 65: 379-84.
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 379-384
-
-
FLEISCHMANN, R.1
BAUMGARTNER, S.W.2
WEISMAN, M.H.3
-
23
-
-
47949106400
-
Efficacy and safety of abatacept or infliximab versus placebo in ATTEST: A phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
-
SCHIFF M, KEISERMAN M, CODDING C et al.: Efficacy and safety of abatacept or infliximab versus placebo in ATTEST: a phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008; 67: 1096-103.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 1096-1103
-
-
SCHIFF, M.1
KEISERMAN, M.2
CODDING, C.3
-
24
-
-
0034735842
-
-
LIPSKY PE, DESIREE MM, VAN DER HEIDJE MD et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 22.
-
LIPSKY PE, DESIREE MM, VAN DER HEIDJE MD et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 22.
-
-
-
-
25
-
-
38749119069
-
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
-
TAKEUCHI T, TATSUKI Y, NOGAMI Y et al.: Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 189-94.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 189-194
-
-
TAKEUCHI, T.1
TATSUKI, Y.2
NOGAMI, Y.3
-
26
-
-
38749088727
-
The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy
-
VAN DER HEIJDJE D, BURMESTER G, MELOGOMES J et al.: The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. Ann Rheum Dis 2008; 67: 182-8.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 182-188
-
-
VAN DER HEIJDJE, D.1
BURMESTER, G.2
MELOGOMES, J.3
-
27
-
-
34447521875
-
Anti-tumor necrosis factor a therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis
-
SCHNEEWEISS S, SETOGUCHI S, WEINBLATT ME et al.: Anti-tumor necrosis factor a therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 1754-64.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 1754-1764
-
-
SCHNEEWEISS, S.1
SETOGUCHI, S.2
WEINBLATT, M.E.3
-
28
-
-
33646696885
-
Anti-TNF therapy in rheumatoid arthritis and risk of serious infections and malignancies
-
BONGARTZ T, SUTTON AJ, SWEETING, MJ et al.: Anti-TNF therapy in rheumatoid arthritis and risk of serious infections and malignancies. JAMA 2006; 295: 2475-82.
-
(2006)
JAMA
, vol.295
, pp. 2475-2482
-
-
BONGARTZ, T.1
SUTTON, A.J.2
SWEETING, M.J.3
-
29
-
-
22244443784
-
Treatment with tumor necrosis factor blockers is associated with lower incidence of first cardiovascular events in patients with rheumatoid arthritis
-
JACOBSSON LTH, TURRESON C, GULFE A et al.: Treatment with tumor necrosis factor blockers is associated with lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005: 32: 1213-8.
-
(2005)
J Rheumatol
, vol.32
, pp. 1213-1218
-
-
JACOBSSON, L.T.H.1
TURRESON, C.2
GULFE, A.3
-
31
-
-
47849128962
-
Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis
-
SETOGUCHI S, SCHNEEWEISS S, AVORN J et al.: Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 2008; 156: 336-41.
-
(2008)
Am Heart J
, vol.156
, pp. 336-341
-
-
SETOGUCHI, S.1
SCHNEEWEISS, S.2
AVORN, J.3
-
32
-
-
36448971598
-
Mortality rate in veterans with multiple chronic conditions
-
LEE T, SHIELDS AE, VOGELI C et al.: Mortality rate in veterans with multiple chronic conditions. J Gen Intern Med 2007; 22: 403-7.
-
(2007)
J Gen Intern Med
, vol.22
, pp. 403-407
-
-
LEE, T.1
SHIELDS, A.E.2
VOGELI, C.3
-
33
-
-
13444266513
-
Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study
-
MARADIT-KREMERS H, CROWSON CS, NICOLA PJ et al.: Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52: 402-11.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 402-411
-
-
MARADIT-KREMERS, H.1
CROWSON, C.S.2
NICOLA, P.J.3
-
34
-
-
34249796662
-
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment for rheumatoid arthritis in clinical practice: The Research in Active Rheumatoid Arthritis (ReAct) trial
-
BURMESTER G, MARIETTE X, MONTECUCCO C et al.: Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment for rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007; 66: 732-9.
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 732-739
-
-
BURMESTER, G.1
MARIETTE, X.2
MONTECUCCO, C.3
-
35
-
-
25144513375
-
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: Validation of the DAS28 score in patients under infliximab treatment
-
CRUYSSEN BV, VAN LOOY S, WYNS B et al.: DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther 2005; 7: R1063-R1071.
-
(2005)
Arthritis Res Ther
, vol.7
-
-
CRUYSSEN, B.V.1
VAN, L.S.2
WYNS, B.3
-
36
-
-
27744532112
-
Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?
-
MAKINEN H, KAUTIAINEN H, HANNONEN P et al.: Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005; 64: 1410-3.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 1410-1413
-
-
MAKINEN, H.1
KAUTIAINEN, H.2
HANNONEN, P.3
-
37
-
-
35948992182
-
Functional health assessment questionnaire (HAQ) and psychological HAQ are associated with and predicted by different factors in rheumatoid arthritis
-
VERSTAPPEN SM, JACOBS JW, HUISMAN AM et al.: Functional health assessment questionnaire (HAQ) and psychological HAQ are associated with and predicted by different factors in rheumatoid arthritis. J Rheumatol 2007; 34: 1837-40.
-
(2007)
J Rheumatol
, vol.34
, pp. 1837-1840
-
-
VERSTAPPEN, S.M.1
JACOBS, J.W.2
HUISMAN, A.M.3
-
38
-
-
43049143540
-
The relation of hand functions with radiological damage and disease activity in rheumatoid arthritis
-
BIRTANE M, KABAYEL DD, UZUNCA K: The relation of hand functions with radiological damage and disease activity in rheumatoid arthritis Rheumatol Int 2008; 28: 407-12.
-
(2008)
Rheumatol Int
, vol.28
, pp. 407-412
-
-
BIRTANE, M.1
KABAYEL, D.D.2
UZUNCA, K.3
-
39
-
-
36849086538
-
Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in Anti-TNFNaïve Rheumatoid Arthritis
-
FERNANDEZ-NEBRO A, IRIGOYEN MV, IMMACULADA U et al.: Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in Anti-TNFNaïve Rheumatoid Arthritis. J Rheumatol 2007; 34: 2334-42.
-
(2007)
J Rheumatol
, vol.34
, pp. 2334-2342
-
-
FERNANDEZ-NEBRO, A.1
IRIGOYEN, M.V.2
IMMACULADA, U.3
|